Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates

Core Viewpoint - Arcutis Biotherapeutics, Inc. reported quarterly earnings of $0.13 per share, significantly exceeding the Zacks Consensus Estimate of $0.03 per share, and showing an improvement from a loss of $0.09 per share a year ago, indicating a strong earnings surprise of +290.39% [1] Financial Performance - The company achieved revenues of $129.5 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 11.93%, and showing a substantial increase from year-ago revenues of $71.36 million [2] - Over the last four quarters, Arcutis Biotherapeutics has consistently exceeded consensus EPS estimates, achieving this four times [2] Stock Performance and Outlook - Despite the positive earnings report, Arcutis Biotherapeutics shares have declined approximately 7.1% since the beginning of the year, contrasting with the S&P 500's gain of 0.7% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] Earnings Estimates and Industry Context - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $94.6 million, while for the current fiscal year, it is $0.38 on revenues of $470.02 million [7] - The Medical - Biomedical and Genetics industry, to which Arcutis belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable industry outlook that could positively influence stock performance [8]